Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPIRED III
2025-520551-84-00Phase 3Authorised
- Sponsor
- Alloksys Life Sciences
- Start
- Jan 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Systemic Inflammatory Response Syndrome (SIRS), acute kidney failure (AKF) and Perioperative myocardial injury (PMI) comparing RESCAP iv with Placebo (2 arms). Planned start Jan 2025; status: authorised.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)acute kidney failure (AKF)Perioperative myocardial injury (PMI)
Beyond the preview
Go deeper on 2025-520551-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520551-84-00.